Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese

Human Molecular Genetics

Volumn 19, Issue 23, 2010, Pages 4735-4744

  Cha, Pei Chieng ^a   Mushiroda, Taisei ^b   Takahashi, Atsushi ^b   Kubo, Michiaki ^b   Minami, Shiro ^c   Kamatani, Naoyuki ^b   Nakamura, Yusuke ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b RIKEN   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450; WARFARIN;

AGE DISTRIBUTION; AGED; ALGORITHM; ARTICLE; BODY SURFACE; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALGORITHMS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; JAPAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; WARFARIN;

EID: 78149256303     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq389     Document Type: Article

References (50)

1. Johnson, J.A. (2008) Warfarin: an old drug but still interesting. Pharmacotherapy, 28, 1081-1083.
2. Horton, J.D. and Bushwick, B.M. (1999) Warfarin therapy: evolving strategies in anticoagulation. American Family Physician: http:///www.aafp.org/afp/990201ap/635.html (accessed February 2, 2010).
3. Lesko, L.J. (2008) The critical path of warfarin dosing: Finding an optimal dosing strategy using pharmacogenetics. Clin. Pharmacol. Ther., 84, 301-303.
4. Siguret, V., Pautas, E. and Gouin-Thibault, I. (2008) Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin. Vitam. Horm., 78, 247-264.
5. Budnitz, D.S., Shehab, N., Kegler, S.R. and Richards, C.L. (2007) Medication use leading to emergency department visits for adverse drug events in older adults. Ann. Intern. Med., 147, 755-765.
6. Agency for health Care Policy and Research (AHCPR) Life-saving treatments to prevent stroke underused. Press release, September 1995: http://www.ahrq.gov/news/press/stroke.htm (accessed February 2, 2010).
7. Wynne, H.A., Kamali, F., Edwards, C., Long, A. and Kelly, P. (1996) Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing, 25, 429-431.
8. Blann, A., Hewitt, J., Siddiqui, F. and Bareford, D. (1999) Racial background is a determinant of average warfarin dose required to maintain the INR between 3.0 and 4.5. Br. J. Haematol., 107, 207-209.
9. Takahashi, H., Wilkinson, G.R., Nutescu, E.A., Morita, T., Ritchie, M.D., Scordo, M.G., Pengo, V., Barban, M., Padrini, R., Ieiri, I. et al. (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance doses of warfarin in Japanese, Caucasians and African Americans. Pharmacogenet. Genomics, 16, 101-110.
10. Johnson, J.A. (2008) Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation, 118, 1383-1393.
11. Holbrook, A.M., Pereira, J.A., Labiris, R., Holbrook, A.M., Pereira, J.A., Labiris, R., McDonald, H., Douketis, J.D., Crowther, N.R. and Wells, P.S. (2004) Systematic overview of warfarin and its drug and food interactions. Ann. Intern. Med., 165, 1095-1106.
12. Schurgers, L.J., Teunissen, K.J.F., Hamulyak, K., Knapen, H.J., Vik, H. and Vermeer, C. (2007) Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood, 109, 3279-3283.
13. Gage, B.F., Eby, C., Johnson, J.A., Deych, E., Rieder, M.J., Ridker, P.M., Milligan, P.E., Grice, P., Lenzini, P., Rettie, A.E. et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Thromb. Haemost., 84, 326-331.
14. Sconce, E.A., Khan, T.I., Wynne, H.A., Avery, P., Monkhouse, L., King, B.P., Wood, P., Kesteven, P., Daly, A.K. and Kamali, F. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106, 2329-2333.
15. Wadelius, M., Chen, L.Y. and Downes, K. (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J., 5, 262-270.
16. Yuan, H.Y., Chen, J.J., Michael Lee, M.T., Wung, J.C., Chen, Y.F., Charng, M.J., Lu, M.J., Hung, C.R., Wei, C.Y., Chen, C.H. et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet., 14, 1745-1751.
17. Mushiroda, T., Ohnishi, Y., Saito, S., Takahashi, A., Kikuchi, Y., Saito, S., Shimomura, H., Wanibuchi, Y., Suzuki, T. and Kamatani, N. (2006) Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J. Hum. Genet., 51, 249-253.
18. Bristol-Myers Squibb Company. Coumadin labeling approved 8/16/2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009218s105lblv2.pdf (accessed February 2, 2010).
19. Schelleman, H., Chen, J., Chen, Z., Christie, J., Newcomb, C.W., Brensinger, C.M., Price, M., Whitehead, A.S., Kealey, C., Thorn, C.F. et al. (2008) Dosing algorithms to predict therapeutic warfarin dose in Caucasians and African Americans. Clin. Pharmacol. Ther., 84, 332-339.
20. Perlini, J.A., Struchiner, C.J., Silva-Assunção, E., Santana, I.S.C., Rangel, F., Ojopi, E.B., Dias-Neto, E. and Suarez-Kurtz, G. (2008) Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther., 84, 722-728.
21. Lee, M.T., Chen, C.H., Chou, C.H., Lu, L.S., Chuang, H.P., Chen, Y.T., Saleem, A.N., Wen, M.S., Chen, J.J., Wu, J.Y. et al. (2009) Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics, 10, 1905-1913.
22. Cavallari, L.H., Langaee, T.Y., Momary, K.M., Shapiro, N.L., Nutescu, E.A., Coty, W.A., Viana, M.A., Patel, S.R. and Johnson, J.A. (2010) Genetic and Clinical Predictors of Warfarin Dose Requirements in African Americans. Clin. Pharmacol. Ther., 87, 459-464.
23. Klein, T.E., Altman, R.B., Eriksson, N., Gage, B.F., Kimmel, S.E., Lee, M.T., Limdi, N.A., Page, D., Roden, D.M. et al.; International Warfarin Pharmacogenetics Consortium. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med., 360, 753-764.
24. Wadelius, M. and Pirmohamed, M. (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J., 7, 99-111.
25. Wadelius, M., Sorlin, K., Wallerman, O., Karlsson, O., Yue, Q.Y., Magnusson, P.K.E., Wadelius, C. and Melhus, H. (2004) Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J., 4, 40-48.
26. Wadelius, M., Chen, L.Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R. and Deloukas, P.Z. (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet., 121, 23-34.
27. Kohnke, H., Sorlin, A.K., Granath, A.G. and Wadelius, M. (2005) Warfarin dose related to apolipoprotein E (APOE) genotype. Eur. J. Clin. Pharmacol., 61, 381-388.
28. Kohnke, H., Scordo, M.G., Pengo, V., Padrini, R. and Wadelius, M. (2005) Apolipoprotein E (APOE) and warfarin dosing in an Italian population. Eur. J. Clin. Pharmacol., 61, 781-783.
29. Kimmel, S.E., Christie, J., Kealey, C., Chen, Z., Price, M., Thorn, C.F., Brensinger, C.M., Newcomb, C.W. and Whitehead, A.S. (2007) Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J., 8, 53-60.
30. Caldwell, M.D., Berg, R.L., Zhang, K.Q., Glurich, I., Schmelzer, J.R., Yale, S.H., Vidaillet, H.J. and Burmester, J.K. (2007) Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res., 5, 8-16.
31. Wadelius, M., Chen, L.Y., Lindh, J.D., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D. et al. (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood, 113, 784-792.
32. Cooper, G.M., Johnson, J.A., Langaee, T.Y., Feng, H., Stanaway, I.B., Schwarz, U.I., Ritchie, M.D., Stein, C.M., Roden, D.M., Smith, J.D. et al. (2008) A genome-wide scan for common genetic variants with a large influence on therapeutic warfarin dose. Blood, 112, 1022-1027.
33. Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W. et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet., 5, e1000433.
34. McDonald, M.G., Rieder, M.J., Nakano, M., Hsia, C.K. and Rettie, A.E. (2009) CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol., 75, 1337-1346.
35. Caldwell, M.D., Awad, T., Johnson, J.A., Gage, B.F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T.Y., Eby, C. et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood, 111, 4106-4112.
36. Borgiani, P., Ciccacci, C., Forte, V., Sirianni, E., Novelli, L., Bramanti, P. and Novelli, G. (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics, 10, 261-266.
37. Pautas, E., Moreau, C., Gouin-Thibault, I., Golmard, J.L., Mahe, I., Legendre, C., Taillandier-Heriche, E., Durand-Gasselin, B., Houllier, A.M., Verrier, P. et al. (2010) Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther., 87, 57-64.
38. Perez-Andreu, V., Roldan, V., Anton, A.I., Garcia-Barbera, N., Corral, J., Vicente, V. and Gonzalez-Conejero, R. (2009) Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood, 113, 4977-4979.
39. Teichert, M., Eijgelsheim, M., Rivadeneira, F., Uitterlinden, A.G., van Schaik, R.H., Hofman, A., De Smet, P.A., van Gelder, T., Visser, L.E. and Stricker, B.H. (2009) A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet., 18, 3758-3768.
40. Heimark, L.D., Wienkers, L., Kunze, K., Gibaldi, M., Eddy, A.C., Trager, W.F., O'Reilly, R.A. and Goulart, D.A. (1992) The mechanism of the interaction between amiodarone and warfarin in humans. Clin. Pharmacol. Ther. 51, 398-407.
41. Kirchheiner, J. and Brockmöller, J. (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther., 77, 1-16.
42. Man, M., Farmen, M., Dumaual, C., Teng, C.H., Moser, B., Irie, S., Noh, G.J., Njau, R., Close, S., Wise, S. et al. (2010) Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with Ccomparison to Caucasians and Africans. J. Clin. Pharm., 50, 929-940.
43. Kimura, R., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K., Otsuki, T., Okayama, A., Minematsu, K., Naritomi, H. et al. (2007) Genotypes of vitamin K epoxide reductase, (-glutamly carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res., 120, 181-186.
44. The Leading Project for Personalized Medicine. http://biobankjp.org/
45. Ohnishi, Y., Tanaka, T., Ozaki, K., Yamada, R., Suzuki, H. and Nakamura, Y. (2001) A high-throughput SNP typing system for genome-wide association studies. J. Hum. Genet., 46, 471-477.
46. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J. et al. (2007) PLINK: a toolset for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet., 81, 559-575.
47. Purcell, S. (2008) PLINK (v1.02) Manual: a whole-genome association toolset. http://pngu.mgh.harvard.edu/~purcell/plink/
48. Ge, D., Zhang, K., Need, A.C., Martin, O., Fellay, J., Urban, T.J., Telenti, A. and Goldstein, D.B. (2008) WGAViewer: software for genomic annotation of whole genome association studies. Genome Res., 18, 640-643.
49. R statistical environment version 2.7.10. http://cran.r-project.org/
50. Abecasis, G. and Willer, C. (2007) METAL user manual. http://www.sph.umich.edu/csg/abecasis/Metal/index.html